Cost-effectiveness of exercise programs in type 2 diabetes

International Journal of Technology Assessment in Health Care

Volumn 28, Issue 3, 2012, Pages 228-234

  Coyle, Doug ^a,b   Coyle, Kathryn ^c   Kenny, Glen P ^a   Boulé, Normand G ^a,d   Wells, George A ^a,e   Fortier, Michelle ^a   Reid, Robert D ^e   Phillips, Penny ^b   Sigal, Ronald J ^a,f  

^a UNIVERSITY OF OTTAWA   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c Applied Health Economic Research Unit   (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

^e UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^f UNIVERSITY OF CALGARY   (Canada)

Author keywords

aerobic exercise; Cost effectiveness; resistance exercise; type 2 diabetes mellitus

Indexed keywords

ADDITIONAL COSTS; AEROBIC EXERCISE; CLINICAL OUTCOME; CLINICAL TRIAL; CONTROL GROUPS; ECONOMIC MODELS; EXERCISE PROGRAMS; EXERCISE TRAINING; GLYCEMIC CONTROL; INCREMENTAL COST; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIAL; RESISTANCE EXERCISE; TYPE 2 DIABETES MELLITUS; TYPE-2 DIABETES;

COST EFFECTIVENESS; COSTS;

COST BENEFIT ANALYSIS;

ADULT; AEROBIC EXERCISE; AGED; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIABETIC PATIENT; FEMALE; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESISTANCE TRAINING; TREATMENT DURATION;

ADULT; AGED; COMBINED MODALITY THERAPY; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; EXERCISE; FEMALE; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; RESISTANCE TRAINING;

EID: 84866366552     PISSN: 02664623     EISSN: 14716348     Source Type: Journal    
DOI: 10.1017/S0266462312000256     Document Type: Article

References (25)

1. Bertram MY, Lim SS, Barendregt JJ, Vos T. Assessing the cost-effectiveness of drug and lifestyle intervention following opportunistic screening for pre-diabetes in primary care. Diabetologia. 2010;53:875-881.
2. Boulé NG, Haddad E, Kenny GP, Wells GA, Sigal RJ. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: A meta-analysis of controlled clinical trials. JAMA. 2001;286:1218-1227. (Pubitemid 33015552)
3. Brazier J, Roberts, Deverill M. The estimation of a preference based measure of health from the SF36. J Health Econ. 2002;21:271-292. (Pubitemid 34143147)
4. Briggs A, Sculpher M, Buxton M. Uncertainty in the economic evaluation of health care technologies: The role of sensitivity analysis. Health Econ. 1994;3:95-104.
5. Briggs AH. Handling uncertainty in cost-effectiveness models. Pharma-coeconomics. 2000;17:479-500. (Pubitemid 30398806)
6. Brun JF, Bordenave S, Mercier J, Jaussent A, Picot MC, Préfaut C. Cost-sparing effect of twice-weekly targeted endurance training in type 2 diabetics: A one-year controlled randomized trial. Diabetes Metab. 2008;34:258-265.
7. CADTH. Guidelines for the economic evaluation of health technologies: Canada [3rd Edition]. Ottawa: CADTH; 2006.
8. Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making. 2002;22:340-349. (Pubitemid 34791321)
9. Clarke PM, Gray AM, Briggs A, et al. A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 68) Outcomes Model. Diabetologia. 2004;47:1747-1759. (Pubitemid 40022410)
10. Coyle D, Palmer AJ, Tam R. Economic evaluation of PioglitazoneHCl in the management of Type 2 Diabetes Mellitus in Canada. Pharmacoeco-nomics. 2002;20:31-42. (Pubitemid 34564436)
11. Doubilet P, Begg CB, Weinstein MC, et al. Probabilistic sensitivity analysis using Monte Carlo simulation: A practical approach. Med Decis Making. 1985;5:157-177. (Pubitemid 16130640)
12. Eves ND, Plotnikoff RC. Resistance Training and Type 2 Diabetes. Considerations for implementation at the population level. Diabetes Care. 2006;29:1933-1941. (Pubitemid 44156659)
13. Goeree R, Lim ME, Hopkins R, et al. Prevalence, total and excess costs of diabetes and related complications in Ontario, Canada. Can J Diabetes. 2009;33:35-45.
14. Herman WH, Hoerger TJ, Brandle M, et al. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med. 2005;142:323-332. (Pubitemid 40293405)
15. Lamy A, Yusuf S, Pogue J, Gafni A. Cost implications of the use of ramipril in high-risk patients based on the Heart Outcomes Prevention Evaluation (HOPE) study. Circulation. 2003;107:960-965. (Pubitemid 36258717)
16. Reid RD, Tulloch HE, Sigal RJ, et al. Effects of aerobic exercise, resistance exercise or both, on patient-reported health status and well-being in type 2 diabetes mellitus: A randomised trial. Diabetologia. 2010;53:632-640.
17. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997;20:1183-1197.
18. Sapsford R. Deputy Minister's response to the investigation into the Ministry of Health and Long-Term Care's decision-making concerning the funding of Avastin for colorectal cancer patients. Letter dated August 26th 2009.
19. Selvin E, Marinopoulos S, Berkenblit G, et al. Meta-analysis: Glycosy-lated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004;141:421-431.
20. Sigal RJ, Kenny GP, Boulé NG, et al. Effects of aerobic exercise, resistance exercise, or both on glycemic control in type 2 diabetes: A randomized trial. Ann Intern Med. 2007;147:357-369. (Pubitemid 351664536)
21. Snowling NJ, Hopkins WG. Effectsof different modesofexercise training on glucose control and risk factors for complications in type 2 diabetic patients: A meta-analysis. Diabetes Care. 2006;29:2518-2527. (Pubitemid 44912265)
22. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ. 2000;321:405-412. (Pubitemid 30609442)
23. Thomas DE, Elliott EJ, Naughton GA. Exercise for type 2 diabetes mel-litus. Cochrane Database Syst Rev. 2006;3:CD002968.
24. van Hout BA, Al MJ, Gordon GS, et al. Costs, effects and C/E ratios alongside a clinical trial. Health Econ. 1994;3:309-319.
25. Ware JE, Snow KK, Kolinski M, Gandeck B.SF-36 Health survey manual and interpretation guide. Boston, MA: The Health Institute, New England Medical Centre; 1993.